Actively Recruiting
DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study
Led by Queen Mary Hospital, Hong Kong · Updated on 2025-07-24
50
Participants Needed
1
Research Sites
38 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the relationship between new Disseminated Intravascular Coagulation (DIC) markers and thrombin generation parameters with blood clotting and bleeding complications in patients receiving Extracorporeal Membrane Oxygenation (ECMO) support. This observational study aims to better understand these markers in the context of ECMO-related complications, with oversight by Queen Mary Hospital in Hong Kong. The study observes adult patients admitted to intensive care units who require either veno-arterial (VA) or veno-venous (VV) ECMO support. Monitoring includes diagnostic testing of DIC markers and thrombin generation parameters to compare findings between patients who do and do not experience clotting or bleeding events during their ECMO treatment. Participants are evaluated from the start to the end of their ECMO support, which typically lasts about 5 days to 1 week but can vary. Researchers track a combined outcome of thrombotic and hemorrhagic events throughout this period. The study collects clinical data to help understand these complications, with participant involvement lasting the duration of ECMO support and data analysis continuing thereafter.
CONDITIONS
Brief Title
DIC Markers and Thrombin Generation Parameters in Patients on ECMO Support: a Pilot Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Admission to the mixed medical-surgical intensive care units of Queen Mary Hospital or Tuen Mun Hospital in Hong Kong
- Require either veno-arterial (VA) or veno-venous (VV) extracorporeal membrane oxygenation (ECMO) support
You will not qualify if you...
- Patients who are on central VA-ECMO support
- Patients with missing clinical data
- Patients with pre-existing thromboembolism requiring long term anticoagulation prior to ECMO cannulation
- Post-operative admissions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From the start of ECMO support to the end of ECMO support (which can be variable, typically around 5 days to 1 week)
Participants undergo observation of DIC markers and thrombin generation parameters while on ECMO support.
1 to 2 visits depending on clinical status
Duration - Up to 1 week after ECMO support ends
Participants are observed for thrombotic and hemorrhagic events following ECMO support.
Visits as needed based on clinical follow-up
Trial Site Locations
Total: 1 location
1
Queen Mary Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
W
Wincy Ng
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here